StrideBio Announces Closing of $81.5M Series B Financing

Proceeds to advance structure-guided AAV capsid engineering platform and pipeline of novel gene therapy candidates into the clinic, including four new wholly-owned programs

Financing will also support organizational growth and GMP manufacturing expansion, building on the company’s current 1000 liter scale in-house production process

Research Triangle Park, N.C., Mar. 16, 2021 – StrideBio, Inc., a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the closing of an oversubscribed Series B funding round, which raised $81.5 million. The financing was co-led by Northpond Ventures and Novo Holdings A/S and included new investors Pontifax, Octagon Capital, Sarepta Therapeutics, CaaS Capital and UF Innovate Ventures, along with existing investors Hatteras Venture Partners, UCB Ventures, Takeda Ventures and Alexandria Venture Investments. In conjunction with the financing, Shaan C. Gandhi, M.D., D.Phil., Director at Northpond Ventures, and Karen Hong, Ph.D., Partner at Novo Ventures, an affiliate of Novo Holdings A/S, have joined the company’s Board of Directors.

“We are very pleased to receive such tremendous support from these top-tier healthcare investors and appreciate the confidence they have placed in our entire team,” said Sapan Shah, Ph.D., Chief Executive Officer of StrideBio. “With this additional funding secured, we will be able to translate next generation gene therapies enabled by our lead engineered capsids into the clinic to benefit patients. We are also delighted to welcome Shaan and Karen to our Board of Directors and look forward to drawing on their expertise as we enter this exciting phase of our development.”

“AAV vectors are proven to be one of the most effective strategies for delivering gene therapies for a variety of human diseases, but there is room for improvement,” said Shaan C. Gandhi, M.D., D.Phil., Director at Northpond Ventures. “StrideBio’s unique approach demonstrates the potential to yield differentiated and best-in-class AAV vectors. The leadership team is highly experienced and we are very impressed with what they have accomplished in advancing their gene therapy programs to date. Northpond is proud to join StrideBio’s circle of investors and co-lead this most recent financing round.”

Financing proceeds will be used to advance the company’s robust pipeline to the clinic, including four new wholly-owned programs targeting monogenic central nervous system (CNS) and cardiovascular disorders. These programs will leverage StrideBio’s lead proprietary AAV capsids with features including reduced seroprevalence, neuronal and cardiovascular tropism, liver de-targeting and enhanced gene transfer efficiency compared to first-generation AAV serotypes. StrideBio will also continue to build on its STRIVE™ platform with the goal to improve safety and reduce doses required for effective gene therapies.

Since StrideBio’s Series A financing in 2018 the company has made significant progress, including executing partnerships with CRISPR Therapeutics, Takeda Pharmaceuticals and Sarepta Therapeutics, generating a robust panel of AAV vectors characterized in multiple, preclinical animal models, as well as successfully establishing and scaling an in-house manufacturing process to 1000L at its facility in RTP. Funds raised as part of the Series B will be used to support continued operational growth and manufacturing capacity expansion, building on the company’s current infrastructure which includes a 6,000 sq ft GMP clean suite.

“We are so excited to support StrideBio as they seek to leverage their innovative AAV capsids to advance their internal and partnered pipeline, bringing multiple programs into the clinic,” said Karen Hong, Ph.D., Partner at Novo Ventures, an affiliate of Novo Holdings A/S. “Novel gene therapies enabled by StrideBio‘s unique lead vectors have the potential to benefit patients with no other treatment options.”

About StrideBio, Inc.

StrideBio, Inc is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) therapies for rare diseases and beyond. We leverage our proprietary structure-inspired adeno-associated virus AAV vector engineering platform (STRIVE™) to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Combined with our genetic construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency, leading to improved treatment outcomes. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C., which houses our offices, research labs and in-house AAV manufacturing facilities. Current investors include Hatteras Venture Partners, Takeda Ventures, UCB Ventures and Alexandria Real Estate Equities, Inc. For more information, please visit www.stridebio.com.

StrideBio Contact
Robert Hughes
984-213-7301
[email protected]

Media Contact

Carolyn Noyes or Susan Sharpe
781-235-3060
MacDougall
[email protected]

StrideBio Expands Leadership Team with Appointment of William Monteith as Chief Operating Officer

Research Triangle Park, N.C., August 11, 2020 – StrideBio, Inc, a leading developer of novel engineered adeno-associated virus (AAV) based gene therapies, today announced the appointment of William (Bill) Monteith as Chief Operating Officer. In this key position, Mr. Monteith will play a lead role in expanding the scale and breadth of StrideBio’s operations, including manufacturing, quality controls and facilities management, as the company advances a robust portfolio of partnered and independent gene therapy programs towards clinical development and ultimate commercialization. In addition, he will work closely with StrideBio’s current leadership team to continue to build a world-class organization and culture as the company undergoes a period of rapid growth in support of its mission to bring novel gene therapies to patients that overcome limitations of first-generation approaches.

Mr. Monteith brings nearly 40 years of experience to StrideBio, having overseen clinical development and commercial scale manufacturing, quality, supply chain and facility operations spanning small molecules, biologics and cell & gene therapies. Mr. Monteith joins StrideBio from Cellectis, where he served as Executive Vice President of Technical Operations. Prior roles have included Chief Operating Officer of Hitachi Chemical Advanced Therapy Solutions, Executive Vice President Technical Operations at Dendreon, as well as site operations and quality positions with Sandoz, Shire, and Wyeth.

“We are very excited to have Bill join the StrideBio leadership team as Chief Operating Officer at such an important time given our trajectory,” stated Sapan Shah, Ph.D., Chief Executive Officer, StrideBio, Inc. “Bill’s significant experience building and expanding infrastructure for leading life science companies as they advance through the clinical development and commercial stage, with an emphasis on cGMP production and quality, matches perfectly with StrideBio’s focus. I am confident Bill will be a fantastic addition as we continue to build an exceptional and capable organization that is advancing a robust pipeline of innovative gene therapies to patients with rare diseases and beyond.”

“This is an incredible time for StrideBio as we transition novel engineered AAV vectors discovered through our innovative structure inspired platform into gene therapy products that can ultimately benefit patients,” noted Mr. Monteith. “I am inspired by our team and the significant progress made to date, which already includes in-house production capability at 1000L scale. I look forward to applying my years of experience to help StrideBio continue to build an exceptional organization with world-class manufacturing, quality and facilities infrastructure that can support our clinical development and commercial goals.”

About StrideBio, Inc.

StrideBio, Inc is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) therapies for rare diseases and beyond. We leverage our proprietary structure-inspired adeno-associated virus AAV vector engineering platform (STRIVE™) to create unique and differentiated vectors that improve upon naturally occurring AAV serotypes to overcome current limitations of first-generation gene therapies. Combined with our genetic construct design expertise and in-house manufacturing capabilities, StrideBio is positioned to generate best-in-class genetic medicines that allow more patients to benefit with maximum efficiency, leading to improved treatment outcomes. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C., which houses our offices, research labs and in-house AAV manufacturing facilities. Current investors include Hatteras Venture Partners, Takeda Ventures, UCB Ventures and Alexandria Real Estate Equities, Inc. For more information, please visit www.stridebio.com.

StrideBio Contact
Robert Hughes
984-213-7301
[email protected]

StrideBio Appoints Maritza McIntyre, Ph.D., as Chief Development Officer

Newly Created Role Will Oversee the Translation of Programs from Research Stage into the Clinic

Research Triangle Park, N.C., April 2, 2020 – StrideBio, Inc., a leading developer of novel adeno-associated viral (AAV) based gene therapies, today announced the appointment of Maritza McIntyre, Ph.D., as Chief Development Officer. In this newly created role, Dr. McIntyre will oversee the translational development of StrideBio’s research-stage gene therapy programs, including Investigational New Drug (IND)-enabling preclinical studies, assay development, regulatory filings and interactions, and initiation of early clinical studies. Both independently and in collaboration with key partners, StrideBio is advancing a pipeline of therapeutic programs that utilize novel engineered AAV capsids discovered in-house that can improve potency, evade neutralizing antibodies and enhance specific tropism to tissues critical for efficacy.

Dr. McIntyre is a virologist with over 20 years of experience in the development, evaluation and regulation of gene therapy, biological and small molecule products. Prior to joining StrideBio, she served as President of Advanced Therapy Partners, Executive Vice President of Regulatory Affairs and Product Development and Gene Therapy Clinical Project Lead at Bamboo Therapeutics, Vice President of Regulatory Affairs at REGENXBIO, and Chief of the Gene Therapy Branch at the U.S. Food and Drug Administration (FDA), among other notable industry leadership roles. Dr. McIntyre is a member of the Boards of the American Society of Gene and Cell Therapy (ASGCT) and GenSight Biologics. She holds a Ph.D. in Virology from the University of Chicago and B.S. in Biology from Wayne State University.

“We are delighted to have Dr. McIntyre join the StrideBio team as Chief Development Officer,” said Sapan Shah, Ph.D., Chief Executive Officer. “She brings an incredible depth of expertise in translational development to StrideBio, drawing on her time at FDA as well as working with numerous companies in the gene therapy space as an executive, advisor and Board member. Dr. McIntyre’s appointment reflects StrideBio’s focus on building the internal capabilities necessary to become a fully integrated gene therapy company and bring innovative therapies to patients with rare diseases and beyond.”

“I am very excited to be joining StrideBio, having previously worked with the founders and followed the company’s progress,” said Dr. McIntyre. “StrideBio has developed a strong and innovative platform to engineer novel AAV capsids in order to improve upon naturally occurring AAV serotypes which, together with in-house manufacturing capabilities, has positioned the company to be a leader in advancing AAV-based gene therapies. StrideBio’s platform has been validated by recent partnerships and a growing pipeline of therapeutic programs, which are testaments to the company’s future promise. I look forward to leading StrideBio’s programs through this next phase of translational development and into the clinic.”

About StrideBio, Inc.

StrideBio is a gene therapy company focused on creating and developing novel adeno-associated viral (AAV) therapies to expand the treatment-eligible population and improve outcomes for patients with serious monogenic rare diseases and beyond. Our STRucture Inspired DEsign approach generates unique and differentiated AAV capsids with improved characteristics including potency, tissue tropism, manufacturability and evasion of pre-existing antibodies. Combined with our wholly owned proprietary cell-line in-house manufacturing capability, the company is positioned to rapidly advance best-in-class genetic medicines. StrideBio is based in a state-of-the-art 24,000-square-foot facility in Research Triangle Park, N.C., which houses the company’s offices, research labs and AAV manufacturing facilities. Current investors include Hatteras Venture Partners, Takeda Ventures, UCB Ventures and Alexandria Real Estate Equities, Inc. For more information, please visit www.stridebio.com.

StrideBio Contact
Robert Hughes
984-213-7301
[email protected]